Recent Updates — SGP

SpyGlass Pharma announced positive four-year interim safety and efficacy results for its Bimatoprost Drug Pad-IOL System (BIM-IOL) in a first-in-human trial involving patients with mild-to-moderate open angle glaucoma or ocular hypertension undergoing cataract surgery. The data showed a 37% reduction in mean intraocular pressure across all dose groups, with 86% of the 21 evaluable patients remaining off topical IOP-lowering drops and 90% maintaining visual acuity of at least 20/25. No product-related adverse events were reported during the follow-up period. The company plans to continue long-term patient monitoring through 2029 while advancing the program toward a New Drug Application submission with the FDA. SpyGlass Pharma is a late-stage biopharmaceutical company developing sustained drug delivery solutions for chronic eye conditions.

On October 1, 2026, SpyGlass Pharma acquired 100% of Advanced Vision Science (AVS) for approximately $13 million in cash. AVS was the existing supplier of intraocular lenses to SpyGlass Pharma and is a subsidiary of Santen Pharmaceutical Co., Ltd. The acquisition secures scalable commercial manufacturing capacity for SpyGlass Pharma's lead product candidate, the BIM-IOL System, and accelerates its ability to expand its lens portfolio with premium options like toric and extended depth-of-focus lenses. Under related agreements, AVS will continue supplying lenses to Santen in Japan and license its technology to other global companies. SpyGlass Pharma is a late-stage biopharmaceutical company developing sustained drug delivery solutions for chronic eye conditions.

SpyGlass Pharma reported a net loss of $19.9 million, or ($0.59) per share, for the quarter ended June 30, 2026, compared to an $8.7 million loss in the prior year period. Cash and short-term investments totaled $234.2 million as of June 30, 2026, which management expects will fund operations through 2028. The company announced that enrollment in its Phase 3 trials for the Bimatoprost Drug Pad-IOL System is on track for completion in 2027, while a first-in-human trial for the BIM-DRS is expected to begin in the second half of 2026. Additionally, SpyGlass appointed Mike Pinder as Vice President of Marketing and secured a new Category III CPT code (+1090T) to support reimbursement for its lead product candidate. SpyGlass Pharma operates in the biopharmaceutical industry, developing drug delivery solutions for glaucoma and ocular hypertension.